Simulations Plus (NASDAQ: SLP) is a life sciences software and services company that develops biosimulation software and provides scientific consulting for pharmaceutical and biotechnology drug development. The company earns revenue through software licenses and consulting engagements covering modeling and simulation across the drug development lifecycle. During the fourth quarter of FY2025, SLP pivoted to an account-based solution selling model focused on solving client pain points across the drug development lifecycle rather than selling discrete products or services. SLP competes against companies that provide biosimulation software, scientific consulting, and screening and testing services, including some competitors with materially larger financial and personnel resources. As of August 31, 2025, the company employed 213 people, over 60% of whom hold advanced degrees in mathematics, chemistry, biomedical engineering, or pharmaceutical sciences.

Revenue model

Revenue comes from software licenses and scientific consulting services. Consulting engagements include physiologically based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP), and other modeling and simulation services provided to clients who lack in-house expertise. Distribution in Japan, China, India, South Korea, and Brazil is handled through independent distributors.

Products and services

Products and services include biosimulation software and consulting services covering PBPK modeling, QSP, and modeling and simulation across discovery, translational research, and clinical development stages. The company supports clients throughout the full drug product lifecycle, including manufacturing changes and biopharmaceutics applications.

Customers and end markets

Customers are pharmaceutical and biotechnology companies requiring modeling and simulation support for drug development. End market demand is driven in part by FDA, EMA, PMDA, NMPA, and Health Canada guidance emphasizing mechanistic PBPK modeling and simulation in clinical pharmacology and biopharmaceutics.

Value-chain role

SLP sits between regulatory science and drug development operations, providing software tools and scientific expertise that support regulatory submissions and internal R&D decisions. Clients send de-identified clinical data to SLP for analysis under HIPAA-compliant processes.

Geographic exposure

Operations are primarily U.S.-based, with independent distributors covering Japan, China, India, South Korea, and Brazil. The company processes data subject to EU GDPR, UK GDPR, and other international data privacy regulations, indicating international client relationships.

Competitors

Companies providing biosimulation software and consulting services, Companies providing screening, testing, and research services not based on biosimulation software, Software companies with products closely related to biosimulation

Source: SEC 10-K, filed 2025-12-01

Industry: Services-Computer Integrated Systems Design Peers: American Well Corp Convey Health Solutions Holdings, Inc. Nutex Health Inc Sharecare, Inc. Health Catalyst, Inc. HealthStream Inc NEXTGEN HEALTHCARE, INC. Phreesia Inc Schrodinger Inc